8-K: Myriad Genetics Announces Preliminary Q4 and Full Year 2024 Results, Issues 2025 Guidance

Myriad Genetics released preliminary unaudited financial results for Q4 and full year 2024, showing revenue growth and provided financial guidance for 2025.

Summary

• Myriad Genetics expects fourth quarter 2024 revenue to be between $209 million and $211 million, a 6% to 7% increase year-over-year.
• Full year 2024 revenue is projected to be between $836 million and $838 million, an 11% increase compared to 2023.
• The company anticipates a GAAP diluted loss per share of $(0.72) to $(0.62) for Q4 2024, with an adjusted diluted EPS of $0.03 to $0.04.
• For the full year 2024, the GAAP loss per share is expected to be between $(1.66) and $(1.56), with an adjusted EPS of $0.14 to $0.15.
• Q4 2024 GAAP net loss is estimated to be between $(65.7) million and $(56.8) million, with adjusted EBITDA between $10 million and $11 million.
• Full year 2024 GAAP loss is projected to be between $(151) million and $(142) million, with adjusted EBITDA between $40 million and $41 million.
• As of December 31, 2024, cash and cash equivalents were approximately $102 million, a $2 million increase from the end of Q3 2024.
• Myriad Genetics has provided full year 2025 revenue guidance of $840 million to $860 million, reflecting a 0% to 3% increase compared to 2024, or 8% to 11% excluding certain revenue impacts.
• The company projects a 2025 gross margin of 69.5% to 70.5%, adjusted operating expenses of $575 million to $595 million, adjusted EBITDA of $25 million to $35 million, and adjusted EPS of $0.07 to $0.11.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to revenue growth and positive adjusted EBITDA, but tempered by GAAP losses and relatively low 2025 growth guidance. The company faces risks and challenges, but the overall outlook is stable.

Positives

• The company experienced revenue growth in both Q4 and full year 2024.
• Cash and cash equivalents increased slightly from the previous quarter.
• Myriad Genetics provided full year 2025 financial guidance, indicating future expectations.
• The company's adjusted EBITDA is expected to be positive for both Q4 and full year 2024.
• The company is projecting positive adjusted EPS for both 2024 and 2025.

Negatives

• The company expects a GAAP net loss for both Q4 and full year 2024.
• The company's 2025 revenue growth is projected to be relatively low at 0% to 3% compared to 2024, or 8% to 11% excluding certain revenue impacts.
• The company's adjusted EBITDA for 2025 is projected to be lower than 2024.
• The company's adjusted EPS for 2025 is projected to be lower than 2024.

Risks

• The preliminary financial results are subject to change after the company's normal quarter and year-end accounting procedures and external audit.
• The company's ability to achieve revenue growth targets and generate sufficient revenue from its existing product portfolio or in launching and commercializing new tests to be profitable is a risk.
• Changes in governmental or private insurers coverage and reimbursement levels for the company's tests could impact revenue.
• Increased competition and the development of new competing tests pose a risk to the company's market share.
• The company may not be able to develop or achieve commercial success for additional tests in a timely manner.
• The company may not be able to secure additional financing to fund its business, if needed, in a timely manner or on favorable terms.
• The company faces risks related to security breaches, loss of data, and other disruptions, including from cyberattacks.
• The company may not be able to keep pace with the rapid technology changes in its industry.
• The company may be unable to comply with financial operating covenants under its credit or lending agreements.
• The company faces risks related to current and future investigations, claims or lawsuits.

Future Outlook

Myriad Genetics anticipates revenue between $840 million and $860 million for full year 2025, with adjusted EBITDA between $25 million and $35 million and adjusted EPS between $0.07 and $0.11. These projections are subject to various risks and uncertainties.

Management Comments

• Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the company's core operating results and comparison of operating results across reporting periods.
• Management also uses non-GAAP financial measures to establish budgets and to manage the company's business.

Industry Context

This announcement comes as the genetic testing and precision medicine industry continues to evolve, with increasing competition and changing reimbursement landscapes. Myriad's results and guidance will be closely watched by investors and competitors alike.

Comparison to Industry Standards

• Myriad Genetics' revenue growth of approximately 11% for full year 2024 is a positive sign, but it is important to compare this to other genetic testing companies such as Exact Sciences (EXAS) and Invitae (NVTA).
• Exact Sciences, for example, has shown strong revenue growth in recent years, while Invitae has faced challenges, including restructuring and cost-cutting measures.
• Myriad's adjusted EBITDA guidance for 2025, ranging from $25 million to $35 million, is relatively low compared to some of its larger competitors, indicating potential challenges in profitability.
• The company's GAAP losses highlight the need for improved operational efficiency and cost management, which is a common challenge in the genetic testing industry.
• The company's 2025 revenue guidance of 0% to 3% growth, or 8% to 11% excluding certain revenue impacts, is below the growth rates of some of the more successful companies in the sector, suggesting that Myriad may need to focus on new product launches and market expansion to improve its growth trajectory.

Stakeholder Impact

• Shareholders will be interested in the company's revenue growth, profitability, and future guidance.
• Employees will be impacted by the company's financial performance and strategic direction.
• Customers will be interested in the company's ability to continue providing high-quality genetic testing services.
• Suppliers will be impacted by the company's financial health and purchasing decisions.
• Creditors will be interested in the company's ability to meet its financial obligations.

Next Steps

• Myriad Genetics plans to release its actual financial results for the fourth quarter and full year 2024 during its earnings call in February 2025.
• The company will continue to execute its business strategy and monitor market conditions.

Key Dates

Keywords

genetic testing, precision medicine, financial results, revenue, EPS, EBITDA, financial guidance, healthcare, genetics